CRISPR Therapeutics Stock Outperforms Broader Market on Expected Earnings Growth
• CRISPR Therapeutics (CRSP) stock closed 1.71% higher, outpacing broader market gains
• CRSP stock has risen 6.15% over the past month, beating the Medical sector's 2.05% gain
• Analysts expect CRSP to report strong 85.11% EPS growth and 14,426,670% revenue growth in upcoming earnings
• Positive estimate revisions reflect analyst optimism and could signal upcoming stock price gains
• Zacks Rank system helps identify stocks likely to outperform; CRSP currently has a Zacks Rank of 3 (Hold)